Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Biocept (BIOC) Climbs 25% Following Q4 Results
March 29, 2021 4:15 PM EDTBiocept (NASDAQ: BIOC) Climbs 25% Following Q4 Results
... MoreBiocept (BIOC) Q4 EPS Beats Consensus, Revenues Beat (Correction)
March 29, 2021 4:08 PM EDT(Updated - March 30, 2021 10:36 AM EDT)
(Update corrects EPS and headline)
Biocept (NASDAQ: BIOC) reported Q4 EPS of $0.14, beating the analyst estimate of ($0.27). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $12.32 million.
Im exceptionally proud of the Biocept team for their enthusiasm and dedication in supporting the COVID-19 testing needs of our community while advancing our oncology business for a strong post-pandemic future, said Michael Nall, President and CEO of Biocept. Our COVID-19 testing has provided valuable information to our clients, which has helped contain viral spread. We received... More
